OKYO Pharma Ltd - Form 20-F Summary
Business Context and Reporting Period
Company: OKYO Pharma Ltd (Guernsey-incorporated, NASDAQ: OKYO)
Reporting Period: Fiscal year ended March 31, 2026
Business Overview: OKYO is a clinical-stage ophthalmology company focused on developing therapies for corneal and anterior segment diseases. The company has no product revenue and is pre-commercialization. Its lead asset, urcosimod (formerly OK-101), is a first-in-class candidate for neuropathic corneal pain (NCP). A secondary candidate, OK-201, remains in early exploratory stages.
Key Financial Metrics (Year Ended March 31, 2026)
| Metric | 2026 (USD) | 2025 (USD) |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(8,949,657) | $(4,706,292) |
| Operating Expenses | $(8,499,553) | $(7,091,897) |
| Research & Development | $(1,809,044) | $(2,254,244) |
| General & Administrative | $(6,690,509) | $(4,837,653) |
| Cash & Cash Equivalents | $14,594,268 | $1,560,902 |
| Short-Term Investments | $6,000,000 | $0 |
| Total Liquidity | $20,594,268 | $1,560,902 |
| Working Capital Surplus | $12,328,828 | $(5,551,590) |
| Accumulated Deficit | $(151,971,569) | $(143,024,972) |
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased by approximately $4.2 million (88%) compared to 2025. This was driven primarily by a $1.85 million increase in General and Administrative (G&A) expenses due to higher option charges, legal fees related to share issuance, executive recruitment, and public relations costs.
- R&D Decrease: R&D expenses decreased by $445,000 (20%) due to the settlement of patent invoices for BAM8 and Chemerin.
- Liquidity Surge: Total cash and short-term investments increased from $1.56 million to $20.6 million. This was fueled by a public offering in February 2026 raising approximately $20 million (gross), with the underwriter exercising its option to purchase additional shares, bringing total gross proceeds to approximately $23 million.
- Debt Conversion: Convertible loan notes totaling $950,000 and accrued interest were converted into 1,688,493 shares in October 2025, eliminating related debt obligations.
- Tax Position: The company recognized a tax charge of $7,987 in 2026 (vs. a credit of $3.26 million in 2025). The 2025 credit was due to R&D tax receipts and provisions; the 2026 charge was due to IRS payments.
Guidance, Outlook, and Management Commentary
- Clinical Progress (Urcosimod):
- Phase 2 Results: A Phase 2 trial for NCP was stopped early after 18 patients completed dosing due to compelling pain relief data. The 0.05% dose showed a mean pain reduction of 5.5 points vs. 2.75 for placebo. Exploratory data indicated potential corneal nerve restoration.
- Regulatory Milestones: Received FDA Fast Track designation (May 2025). Held successful Type C and Type D meetings with the FDA in Jan 2026 and July 2026, respectively.
- Phase 3 Plan: The FDA endorsed a single-dose Phase 3 study design named "NEPTUNE," targeting approximately 111 subjects in a 2:1 randomization (0.05% urcosimod vs. placebo) across the US and Europe.
- Management Changes: Robert J. Dempsey was appointed CEO in January 2026, bringing extensive ophthalmology commercialization experience. Flavio Mantelli, MD, PhD, was appointed Chief Medical Officer in February 2026.
- Outlook: Management believes current cash resources ($20.6 million) are sufficient to fund the upcoming Phase 3 trial and ongoing operations for the foreseeable future. However, the company expects to incur significant losses for the foreseeable future and will need to raise additional capital in the longer term.
- Risks: Key risks include the high failure rate of clinical trials, dependence on third-party manufacturers and CROs, potential inability to secure regulatory approval, and the need for future equity financing which may be dilutive.
Key Facts for Investor Verification
- Cash Runway: Verify the sufficiency of the $20.6 million cash balance to fund the global Phase 3 "NEPTUNE" trial and operations through the next 12-18 months, given the historical burn rate of ~$6 million annually in operating cash flow.
- Phase 3 Design: Confirm the final protocol details for the NEPTUNE trial, specifically the sample size (111 subjects) and the statistical power of a single-arm or single-trial registration pathway as discussed with the FDA.
- Dilution Risk: Monitor future capital raising activities. The company has a history of equity financing and convertible debt; further raises will likely dilute existing shareholders.
- Intellectual Property: Review the status of the license agreement with On Target Therapeutics (OTT) and Tufts Medical Center, including the $4.9 million in potential development milestones and $37 million in sales milestones.
- Going Concern: While management asserts a going concern basis, verify the assumptions regarding the timing of the Phase 3 trial and the ability to access capital markets if the trial timeline extends or costs exceed projections.